Stay updated with breaking news from Bugra Basat. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Orpha Labs AG, a clinical-stage biopharmaceutical company focused on diseases with unmet needs, today announced the initiation of the Phase III...
BAAR, Switzerland, Feb. 23, 2022 /PRNewswire/ -- Orpha Labs AG, a clinical-stage biopharmaceutical company focused on diseases with unmet needs, today announced the initiation of the Phase III
BAAR, Switzerland, Feb. 23, 2022 /PRNewswire/ -- Orpha Labs AG, a clinical-stage biopharmaceutical company focused on diseases with unmet needs, t...
First patient to receive first Orpha Labs drug this week 09.02.2021 08:46 Zug-based Orpha Labs AG launched its compassionate use program to make its lead product ORL-101 available to physicians providing care for Leukocyte Adhesion Deficiency Type II (LAD-II) patients. The Israeli Ministry of Health approved the use. The first patient will receive ORL-101 in Israel this week. Orpha Labs is committed to discovering and developing treatments for ultra-rare diseases. One of these diseases is Leukocyte Adhesion Deficiency Type II. According to Orphanet LAD II is characterized by recurrent bacte...
(0) First Patient to Receive ORL-101 in Israel This Week BAAR, Switzerland, Feb. 8, 2021 /PRNewswire/ -- Orpha Labs AG today announced its compassionate use program to make ORL -101 available to physicians providing care for Leukocyte Adhesion Deficiency Type II (LAD-II) patients. ORL-101 is a novel formulation of an ultra-pure L-fucose currently in development for the treatment of LAD II patients. The Israeli Ministry of Health (MOH) approved the use of ORL-101 for LAD-II patients under Orpha Labs' compassionate use program. Orpha Labs expects to enroll LAD-II patients in a Phase III trial ...